Obinutuzumab

Common brands: Gazyva, Venclexta, Rituxan, Cyclophosphamide, Frindovyx

Top reporter: Genentech, Inc.

CD20-directed Cytolytic Antibody [EPC]Corticosteroid [EPC]Alkylating Drug [EPC]BCL-2 Inhibitor [EPC]Kinase Inhibitor [EPC]
15,802
Total Reports
8,904
Serious Reports
2,119
Death Reports
30
Reported Reactions
Death Report Ratio: High (13.41%)

Patient Demographics

Male
7,646
Female
5,316

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Obinutuzumab.

# Reaction Reports % of Total
1 OFF LABEL USE 1,773
9.3%
2 NEUTROPENIA 1,312
6.8%
3 COVID-19 1,076
5.6%
4 FEBRILE NEUTROPENIA 1,031
5.4%
5 PYREXIA 968
5.1%
6 DISEASE PROGRESSION 899
4.7%
7 THROMBOCYTOPENIA 897
4.7%
8 INFUSION RELATED REACTION 831
4.3%
9 PNEUMONIA 763
4.0%
10 ANAEMIA 698
3.6%
11 INFECTION 593
3.1%
12 ATRIAL FIBRILLATION 592
3.1%
13 DEATH 524
2.7%
14 NAUSEA 507
2.6%
15 NO ADVERSE EVENT 506
2.6%
16 MYELOSUPPRESSION 500
2.6%
17 DYSPNOEA 491
2.6%
18 CHILLS 482
2.5%
19 DIARRHOEA 477
2.5%
20 CYTOKINE RELEASE SYNDROME 466
2.4%
21 CYTOPENIA 464
2.4%
22 DRUG INEFFECTIVE 452
2.4%
23 PLATELET COUNT DECREASED 410
2.1%
24 FATIGUE 388
2.0%
25 HAEMORRHAGE 381
2.0%
26 ASPERGILLUS INFECTION 367
1.9%
27 HYPOTENSION 352
1.8%
28 WHITE BLOOD CELL COUNT DECREASED 326
1.7%
29 TUMOUR LYSIS SYNDROME 320
1.7%
30 VOMITING 309
1.6%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.